Head-To-Head Survey: RenovoRx (NASDAQ:RNXT) & Nektar Therapeutics (NASDAQ:NKTR)

RenovoRx (NASDAQ:RNXT) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility and Risk

RenovoRx has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for RenovoRx and Nektar Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	0	1	3	0	2.75
Nektar Therapeutics	1	3	2	0	2.17

RenovoRx currently has a consensus price target of $8.33, indicating a potential upside of 634.21%. Nektar Therapeutics has a consensus price target of $3.00, indicating a potential upside of 132.56%. Given RenovoRx’s stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Nektar Therapeutics.

Institutional and Insider Ownership

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares RenovoRx and Nektar Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RenovoRx	N/A	-2,860.14%	-203.57%
Nektar Therapeutics	-195.02%	-107.31%	-38.08%

Earnings & Valuation

This table compares RenovoRx and Nektar Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	N/A	N/A	-$10.23 million	($0.72)	-1.58
Nektar Therapeutics	$90.12 million	2.63	-$276.06 million	($0.92)	-1.40

RenovoRx has higher earnings, but lower revenue than Nektar Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

RenovoRx beats Nektar Therapeutics on 8 of the 12 factors compared between the two stocks.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.